Avista to back eMolecules

Avista Capital Partners has agreed to invest in eMolecules, an e-procurement platform for high-value chemicals and bioreagents used by pharmaceutical companies in drug discovery.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this